John RPh - Precision BioSciences CFO Officer
| DTIL Stock | USD 3.96 0.03 0.75% |
CFO
John RPh is CFO Officer of Precision BioSciences
| Age | 59 |
| Address | 302 East Pettigrew St., Durham, NC, United States, 27701 |
| Phone | 919 314 5512 |
| Web | https://precisionbiosciences.com |
Precision BioSciences Management Efficiency
The company has return on total asset (ROA) of (0.4534) % which means that it has lost $0.4534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0516) %, meaning that it created substantial loss on money invested by shareholders. Precision BioSciences' management efficiency ratios could be used to measure how well Precision BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Precision BioSciences' Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.05 this year, although the value of Return On Capital Employed will most likely fall to (0.26). At this time, Precision BioSciences' Return On Tangible Assets are quite stable compared to the past year. Intangibles To Total Assets is expected to rise to 0.01 this year, although the value of Non Current Assets Total will most likely fall to about 33.6 M.Similar Executives
| Found 5 records | CFO Age | ||
| Lisa MBA | Fractyl Health Common | 59 | |
| Edward Albini | Sutro Biopharma | 66 | |
| Steve Forte | Repare Therapeutics | 45 | |
| Edward MBA | Sutro Biopharma | 68 | |
| Neha Krishnamohan | Artiva Biotherapeutics Common | 38 | |
Management Performance
| Return On Equity | -2.05 | ||||
| Return On Asset | -0.45 |
Precision BioSciences Leadership Team
Elected by the shareholders, the Precision BioSciences' board of directors comprises two types of representatives: Precision BioSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Precision. The board's role is to monitor Precision BioSciences' management team and ensure that shareholders' interests are well served. Precision BioSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Precision BioSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maurissa Messier, Senior Communications | ||
| Fayaz Khazi, Chief Systems | ||
| Derek Jantz, Chief CoFounder | ||
| Jefferson Smith, CoFounder Officer | ||
| Cassie Gorsuch, Chief Officer | ||
| Bruce Stevens, Vice Compliance | ||
| John Kelly, Chief Officer | ||
| Dario JD, General Secretary | ||
| Juli Blanche, Chief Officer | ||
| Garrett Gincley, Head Manufacturing | ||
| Mei Burris, Director Finance | ||
| Cindy Atwell, Chief Officer | ||
| Neil MS, Manufacturing Chemistry | ||
| John RPh, CFO Officer | ||
| Alan MD, Chief Officer | ||
| Heather King, Director PR | ||
| Michael Amoroso, CEO President | ||
| Shane Barton, Co VP | ||
| Naresh Tanna, Chief Relations | ||
| Dario Scimeca, General Secretary | ||
| MPH MD, Senior Development |
Precision Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Precision BioSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.05 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 80.18 M | ||||
| Shares Outstanding | 24.07 M | ||||
| Shares Owned By Insiders | 5.86 % | ||||
| Shares Owned By Institutions | 44.51 % | ||||
| Number Of Shares Shorted | 1.32 M | ||||
| Price To Earning | (6.10) X | ||||
| Price To Book | 5.77 X | ||||
| Price To Sales | 136.57 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. Projected growth potential of Precision fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Precision BioSciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (8.89) | Revenue Per Share | Quarterly Revenue Growth (0.98) | Return On Assets | Return On Equity |
Precision BioSciences's market price often diverges from its book value, the accounting figure shown on Precision's balance sheet. Smart investors calculate Precision BioSciences' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Precision BioSciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Precision BioSciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Precision BioSciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.